BR112015028270A2 - sulfato de dextrano para uso na mobilização de células - Google Patents

sulfato de dextrano para uso na mobilização de células

Info

Publication number
BR112015028270A2
BR112015028270A2 BR112015028270A BR112015028270A BR112015028270A2 BR 112015028270 A2 BR112015028270 A2 BR 112015028270A2 BR 112015028270 A BR112015028270 A BR 112015028270A BR 112015028270 A BR112015028270 A BR 112015028270A BR 112015028270 A2 BR112015028270 A2 BR 112015028270A2
Authority
BR
Brazil
Prior art keywords
dextran sulfate
cell mobilization
cell
mobilization
cells
Prior art date
Application number
BR112015028270A
Other languages
English (en)
Other versions
BR112015028270B1 (pt
Inventor
Waas Anders
Duprez Ida
Original Assignee
Tx Medic Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tx Medic Ab filed Critical Tx Medic Ab
Publication of BR112015028270A2 publication Critical patent/BR112015028270A2/pt
Publication of BR112015028270B1 publication Critical patent/BR112015028270B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

resumo sulfato de dextrano para uso na mobilização de células o sulfato de dextrano numa faixa de 3500 e 9500 da é utilizado para mobilizar células, tais como as células estaminais e/ou progenitoras e certos leucócitos, particularmente linfócitos, para dentro do sangue periférico de um indivíduo. o sulfato de dextrano tem um efeito de mobilização de células muito rápido que implica que qualquer colheita de células pode ser iniciada quase imediatamente após a administração de sulfato de dextrano. 1/1
BR112015028270-9A 2014-05-12 Composição de mobilização de células para uso na mobilização de células progenitoras e/ou células tronco BR112015028270B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1350584A SE537742C2 (sv) 2013-05-13 2013-05-13 Dextransulfat för cellmobilisering
PCT/SE2014/050576 WO2014185851A1 (en) 2013-05-13 2014-05-12 Dextran sulfate for use in mobilization of cells

Publications (2)

Publication Number Publication Date
BR112015028270A2 true BR112015028270A2 (pt) 2017-07-25
BR112015028270B1 BR112015028270B1 (pt) 2023-08-15

Family

ID=

Also Published As

Publication number Publication date
WO2014185851A1 (en) 2014-11-20
ES2780907T3 (es) 2020-08-27
SE1350584A1 (sv) 2014-11-14
SE537742C2 (sv) 2015-10-13
CA2912366A1 (en) 2014-11-20
JP6339668B2 (ja) 2018-06-06
PL2999478T3 (pl) 2020-10-19
US10258642B2 (en) 2019-04-16
DK2999478T3 (da) 2020-04-14
US20160120897A1 (en) 2016-05-05
JP2016519143A (ja) 2016-06-30
EP2999478A4 (en) 2017-02-22
CN105358159B (zh) 2018-08-28
CA2912366C (en) 2021-04-06
EP2999478A1 (en) 2016-03-30
CN105358159A (zh) 2016-02-24
EP2999478B1 (en) 2020-01-15

Similar Documents

Publication Publication Date Title
AR097901A1 (es) Agente beneficioso con partículas de administración
CL2015002941A1 (es) Usos terapéuticos de empaglifozina
CL2014003225A1 (es) Composición que comprende un agente de control biológico y un fungicida.
NI201500067A (es) Compuestos de pirrolopirimidina como inhibidores de quinasa
BR112016015029A2 (pt) Artigo abrasivo incluindo partículas abrasivas moldadas
WO2014153069A3 (en) Compositions and methods for reprogramming hematopoietic stem cell lineages
TR201909582T4 (tr) Pirimido[4,5-b]indol türevleri ve hematopoetik kök hücrelerinin ekspresyonunda bunlarin kullanimi.
CL2014000494A1 (es) Compuestos derivados de imidazo[1,2-a]piridina, como inhibidores de las quinasas pdgfr y/o c-kit; composicion farmaceutica que los comprende; y su uso para tratar una enfermedad asociada con mastocitos, una enfermedad respiratoria, una enfermedad metabolica, un trastorno autoinmune, una enfermedad dermatologica, entre otras.
NI201100083A (es) Compuestos que expanden células madre hematopoyéticas.
BR112017001632A2 (pt) conjunto de retenção, prateleira e máquina de lavar louça
CL2016000008A1 (es) Tratamiento de lesiones inflamatorias de rosacea con ivermectina.
BR102012017817A2 (pt) Promoção e rebaixamento de habilidade de agente com base em estado de centro de contacto
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
CL2015002433A1 (es) Imidazopiridazinas sustituidas
BR112014022817A8 (pt) processo de aumento da criopreservação de células biológicas e composição de criopreservação
BR112015028499A2 (pt) Peptídeo para induzir apoptose específica de mastócito e uso do mesmo
TWD189982S (zh) 注射裝置的容器
CO7380754A2 (es) Antígenos asociados con enfermedad inflamantoria del intestino
BR112015022757A2 (pt) composições nutricionais que incluem beta-hidróxi-beta-metilbutirato de cálcio, fosfopeptídeo de caseína, e proteína
BR112015023025A8 (pt) composições antimicrobianas e artigos compreendendo as mesmas
DOP2016000076A (es) Tienouracilcarboxamidas cíclicas y usos de las mismas
BR112015019197A2 (pt) tratamento de doença de enxerto versus hospedeiro em pacientes transplantados
CL2016001130A1 (es) Composiciones sólidas de triglicéridos y usos de estas
BR112016029008A2 (pt) uso de sulfato de dextrana com peso molecular médio abaixo de 10000 da para induzir a angiogênese em um sujeito
BR112015016995A2 (pt) uso de agonistas de receptores alfa 7 nicotínico de acetilcolina para a facilitação do surgimento da anestesia geral

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/05/2014, OBSERVADAS AS CONDICOES LEGAIS